← Leaderboards
Alexander Sparreboom
St. Jude Children'S Research Hospital
$5,976,463
Attributed
$8,229,370
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $863.8K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,229,370 · 5
By mechanism
R01$8,229,370 · 5
Top collaborators
- Navjot Pabla5 shared
- Daniel Addison2 shared
- Sharyn D Baker2 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- William E. Evans$20,051,064
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCellsIn VivoIncidenceMediatingToxic EffectUptakeIn VitroSeveritiesTreatment ProtocolsLeadGeneticAntineoplastic AgentsMouse ModelOrganic Cation TransporterAffectChildResponseEvaluationFutureLifeAdultChemotherapyDose-Limiting
Grant awards (19)
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics$746,337
R01 · FY2025 · HL · contact PI
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics$730,587
R01 · FY2024 · HL · contact PI
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics$512,366
R01 · FY2021 · CA · contact PI
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics$512,366
R01 · FY2020 · CA · contact PI
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics$496,995
R01 · FY2019 · CA · contact PI
Solute Carriers and Oxaliplatin Neurotoxicity$341,706
R01 · FY2019 · CA · contact PI
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics$511,546
R01 · FY2018 · CA · contact PI
Solute Carriers and Oxaliplatin Neurotoxicity$352,275
R01 · FY2018 · CA · contact PI
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics$503,309
R01 · FY2017 · CA · contact PI
Solute Carriers and Oxaliplatin Neurotoxicity$352,275
R01 · FY2017 · CA · contact PI
Solute Carriers and Oxaliplatin Neurotoxicity$311,982
R01 · FY2016 · CA · contact PI
Solute Carriers and Oxaliplatin Neurotoxicity$258,543
R01 · FY2015 · CA · contact PI
Solute Carriers and Oxaliplatin Neurotoxicity$148,632
R01 · FY2015 · CA · contact PI
Organic cation transporter 2 and cisplatin nephrotoxicity$386,808
R01 · FY2014 · CA · contact PI
Organic cation transporter 2 and cisplatin nephrotoxicity$374,845
R01 · FY2013 · CA · contact PI
Organic cation transporter 2 and cisplatin nephrotoxicity$398,576
R01 · FY2012 · CA · contact PI
Organic cation transporter 2 and cisplatin nephrotoxicity$398,671
R01 · FY2011 · CA · contact PI
Organic cation transporter 2 and cisplatin nephrotoxicity$411,104
R01 · FY2010 · CA · contact PI
PHARMACODYNAMICS OF ANTILEUKEMIC AGENTS IN CHILDREN$480,447
R01 · FY2007 · CA · contact PI